Data From BioTime’s OpRegen® Trial in Dry-AMD to be Presented at ARVO on May 8

by Business Wire • 2017/03/15 • 0 Comments

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that a poster presentation based on data from its Phase I/IIa clinical trial of OpRegen® in the advanced form of dry age-related macular degeneration (dry-AMD) will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) on Monday, May 8, 2017, in Baltimore, M

← Global Dry Eye Partnering 2010 to 2017: Deals and Agreements Entered Into by the World’s Leading Healthcare Companies – Research and Markets

New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix’ DEXTENZA™ Following Cataract Surgery →

Post navigation